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Abstract
Background: Matrix metalloproteinases (MMPs) are involved in the degradation of protein components of the
extracellular matrix and thus play an important role in tumor invasion and metastasis. Their expression is related to
the progression of gynecological cancers (e.g. endometrial, cervical or ovarian carcinoma). In this study we
investigated the expression pattern of the 23 MMPs, currently known in humans, in different gynecological cancer
cell lines.
Methods: In total, cell lines from three endometrium carcinomas (Ishikawa, HEC-1-A, AN3 CA), three cervical
carcinomas (HeLa, Caski, SiHa), three chorioncarcinomas (JEG, JAR, BeWo), two ovarian cancers (BG-1, OAW-42) and
one teratocarcinoma (PA-1) were examined. The expression of MMPs was analyzed by RT-PCR, Western blot and
gelatin zymography.
Results: We demonstrated that the cell lines examined can constitutively express a wide variety of MMPs on mRNA
and protein level. While MMP-2, -11, -14 and -24 were widely expressed, no expression was seen for MMP-12, -16, -20,
-25, -26, -27 in any of the cell lines. A broad range of 16 MMPs could be found in the PA1 cells and thus this cell line
could be used as a positive control for general MMP experiments. While the three cervical cancer cell lines expressed
10-14 different MMPs, the median expression in endometrial and choriocarcinoma cells was 7 different enzymes. The
two investigated ovarian cancer cell lines showed a distinctive difference in the number of expressed MMPs (2 vs. 10).
Conclusions: Ishikawa, Caski, OAW-42 and BeWo cell lines could be the best choice for all future experiments on
MMP regulation and their role in endometrial, cervical, ovarian or choriocarcinoma development, whereas the
teratocarcinoma cell line PA1 could be used as a positive control for general MMP experiments.
Background
Tumor invasion and metastasis define malignancy and
are the principal causes of cancer associated death.
Tumor cells are surrounded by the extracellular matrix
(ECM) comprising of proteoglycanes and non-proteogly-
canic matrix components (collagen, laminin, fibronectin
and elastin). Degradation of the extracellular matrix
allows tumor cells to detach from the primary tumor
mass, invade local tissue, intravasate, extravasate and
build new metastatic formations [1]. Currently, four
classes of proteinases are known as being capable of
breaking down nearly all components of the extracellular
matrix: serine proteinases, aspartatic proteases, cystein
proteinases and matrix metalloproteinases (MMPs) [2-4].
Previous studies showed that MMPs facilitate tumor
invasion and metastasis in general. Compared to normal
tissue, in almost all human cancers the expression and
activation of MMPs is increased [5,6]. Also, MMPs play a
role in a multiplicity of physiological processes requiring
tissue remodeling (e.g. wound-healing, embryogenesis,
angiogenesis and ovulation) [2-4]. There is a precise reg-
ulation between activation and inhibition of proteolysis
and this physiological balance seems to be disrupted in
cancer [7].
MMPs are a family of structural and functional related
endopeptidases. Currently, 23 members of the MMP
family are known in humans [2]. MMPs are zinc depen-
dent proteases which are capable of degrading one or
more components of the extracellular matrix. Depending
on their substrate specificity, MMPs are divided into six
subclasses: collagenases, gelatinases, stromelysins, matri-
lysins, membrane-type MMPs and others [2]. MMPs are
synthesized as inactive zymogens. First they remain
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the zinc-ion bound to the catalytic site. After removal of
the propeptide domain, the active site becomes available
to cleave substrates. All MMPs, except MMP-11, are
secreted as inactive zymogens and are activated outside
the cell by other activated MMPs or serine proteases (e.g
trypsin, plasmin, kallikrein) [2-4]. Under physiological
conditions, expression of MMPs is tightly regulated on
an mRNA level (transcription), e.g. activation of MMPs
and inhibition of active MMPs by TIMPs (tissue inhibi-
tors of MMPs).
There is evidence, that the expression of MMPs is
related to the progression of gynecological cancers, as is
such the case for endometrium cancer [8,9], cervical
carcinoma [10-13] and ovarian carcinoma [14-17]. How-
ever, only a few MMP-members were investigated in
these previous studies. In order to enlarge the knowl-
edge on the role of MMPs plays in these cancer entities,
we investigated the expression of all MMPs known in
humans so far by measuring mRNA and protein level in
twelve gynecological cancer cell lines commonly used in
experimental research. We examined cell lines of endo-
metrium carcinoma (Ishikawa, HEC-1-A, AN3 CA),
cervix-carcinoma (HeLa, Caski, SiHa), chorioncarcinoma
(JEG, JAR, BeWo), ovarian cancer (BG-1, OAW-42) and
the teratocarcinoma cell line PA-1.
Until now, only limited data are available on the
expression of MMPs in the cell lines investigated herein.
Giambernardi and colleagues found the expression of
MMP-7, -14, -15, -16 and -17 in HeLa cells on mRNA
level as well as an expression of MMP-12 and MMP-14
mRNAs in JEG cell line using RT-PCR [18]. MMP-14
was also detected in the cervix-carcinoma cell lines
Caski and SiHa [19]. For an overview, data published so
far are summarized in Additional file 1: MMP expres-
sion in gynecological cancer cell lines.
Methods
Cell culture
All the cell lines used were described in Table 1 [20-45]
and obtained from Cell Lines Service (Eppelheim, Ger-
many). Briefly, all cells were cultured in a 1:1 mixture of
DMEM/Ham’s F-12 supplemented with 10% FCS and
10 ng/ml gentamycine (PAA, Coelbe, Germany) at 37°C
in the presence of 5% CO2. Cells were cultured in 75 ml
culture-flasks (Biochrom, Berlin, Germany) as monolayer
culture and harvested at 80-90% confluency using a cell-
scraper (Biochrom). Cells were resuspended and washed
twice in phosphate-buffered saline (PBS). Dry pellets
were frozen at -20°C for RNA and protein extraction.
RNA extraction and cDNA synthesis
Total RNA was extracted from 10
6 cells using RNeasy
mini kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instruction. Total cellular RNA was
eluted in 60 μl RNase free water and stored at -20°C.
Total RNA was transcribed at 42°C for 1 h in a 20 μl
reaction mixture using the RevertAid H Minus First
Strand cDNA synthesis kit (Fermentas, St. Leon-Rot,
Germany) and terminated by heating the samples at
70°C for 10 min. Synthesized cDNAs were stored at
-20°C for further expression analysis.
Semiquantitative RT-PCR
Expression analyses of MMPs were performed using gene
specific primers and optimized reaction conditions as
published previously [46]. Conventional PCR reactions
were performed in a volume of 25 μl containing template
DNA, 2.5 U Taq polymerase, 10 X reaction buffer
with 1.5 mM MgCl2 (Eppendorf, Hamburg, Germany),
200 μM dNTPs (Fermentas), 0.4 μM of both forward and
reverse primers and formamide at a final concentration
of 4%. PCR conditions were optimized for each primer-
pair. Amplification reactions were performed using a Px2
thermal cycler (Techne, Staffordshire, U.K.) and con-
sisted of following steps: 94°C for 5 min, 28-32 cycles at
94°C for 30 sec; optimized annealing temperature for
30 sec and 72°C for 10 min (elongation). The amount of
cDNA was normalized to the intensity of the PCR pro-
ducts of the ubiquitously expressed gene porphobilinogen
deaminase (PBGD). PCR products were separated on a
1% agarose gel and visualized using ethidium-bromide
(Roth, Karlsruhe, Germany). All RT-PCRs were per-
formed in independent triplicates.
Western blotting
For protein extraction, 10
6 cells were lysed in precooled
Ripa-buffer (Pierce, Rockford, Ilinois) containing phospha-
tase inhibitors (Phosphatase Inhibitor Cocktails Set II,
Calbiochem, Germany), proteinase inhibitors (Complete,
Roche, Germany) and 2,5 mM DTT reducing agent
(Dithiothreitol, Sigma, Taufkirchen, Germany). The mix-
ture was incubated for 30 min on ice, combined with
vortexing every 10 min. Cell lysates were clarified of cell
debris by centrifugation at 14.000 × g for 5 min through a
QIAshredder spin column assembly (Qiagen) at 4°C.
Protein concentration was determined by the Bradford-
method [47] using coomassie brilliant blue (Roti-Quant;
Roth, Karlsruhe, Germany). Afterwards, the samples
were mixed in 5 × loading buffer (Fermentas), denatured
at 95°C for 5 min, chilled on ice and stored at -20°C for
further analysis. Equal amounts of proteins (20 μg) were
loaded on a 10% polyacrilamide gel (SDS-PAGE) and elec-
trophoresed. Proteins were then blotted onto a nitrocellu-
lose membrane (Schleicher & Schuell, Dassel, Germany)
for 45 min at 10 V using a semi-dry-transfer unit (PeqLab,
Erlangen, Germany). The membrane was stained with
ponceau-red (Sigma) to verify that the proteins were
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Page 2 of 12blotted. To avoid unspecific binding, the membrane was
blocked with 5% nonfat milk in PBS/Tween (0,05%) at RT
for 1 hour. Subsequently, the membrane was incubated
with the primary antibody at appropriate dilution in 2%
nonfat milk and PBS/Tween at 4°C for 18 hours. Primary
antibodies used are summarized in Table 2. After washing
with PBS, the membrane was incubated with the respec-
tive horseradish peroxidase-conjugated secondary antibo-
dies for 60 min at RT. A monoclonal mouse anti-b-actin
primary antibody, diluted 1: 10.000, (Abcam, Cambridge,
USA) was used as internal control. Immunoblots were
visualized by homemade enhanced chemiluminescence
(ECL) [48] with subsequent exposure on an X-ray film
(Fuji Super RX medical X-ray films; Fuji Photo Film, Dues-
seldorf, Germany).
Gelatin zymography
Cell supernatants were collected after 48 hours incubation
in serum-free medium. Enzymatic activity of MMP-2 and
MMP-9 was measured by gelatinolytic zymography. Con-
ditioned media (20 μl) were incubated with SDS gel sam-
ple buffer (Invitrogen, Carlsbad, USA) for 10 minutes at
room temperature and electrophoresed on 10% Novex
precast zymogram (gelatin) gels (Invitrogen). The gels
were run, renatured and developed according to the man-
ufacturer’s instructions. Briefly, after electrophoresis, the
gels were rinsed twice with Novex Zymogram Renaturing
Buffer (30 minutes per wash at room temperature). The
gels were then rinsed with fresh Novex Zymogram Devel-
oping Buffer and incubated in the same buffer for 18
hours at 37°C. After incubation, the gels were briefly
rinsed in distilled water and stained with Coomassie brilli-
ant blue G250 for 2 hours. The digested area appeared
clear on a blue background, indicating the expression and
activity of gelatinases. The molecular weights of the gelati-
nases in the samples were determined using recombinant
protein molecular weight markers MMP-2 and MMP-9
(R&D Systems, Wiesbaden, Germany).
Table 1 Human gynecological cell lines
Cell line Tissue Cell type Origin Special features Citation
Ishikawa Endometrium Adenocarcinoma Primary tumor ER positive,
PR positive
[20-22]
HEC-1-A Endometrium Adenocarcinoma Primary tumor ER positive
PR positive
[23-25]
AN3-CA Endometrium Adenocarcinoma Metastatic site
(lymph node)
ER positive
PR positive
[26-28]
HeLa Cervix Adenocarcinoma Primary tumor HPV-18 positive [29-31]
Caski Cervix Epidermoid
carcinoma
Metastasis
(small bowel mesentery)
HPV-16 positive
HPV-18 positive
[32,33]
SiHa Cervix Squamous cell
carcinoma
Primary tumor HPV-16 positive [34,35]
JEG Placenta Chorioncarcinoma Primary tumor Produce hCG, HCS, progesterone [36,37]
JAR Placenta Chorioncarcinoma Primary tumor Produce estrogen, progesterone, hCG, HCS [38]
BeWo Placenta Chorioncarcinoma Metastatic site (cerebral
metastasis)
Produce estrogen, progesterone, hCG, HCS, estrone, estriol,
estradiol, keratin
[38-40]
BG_1 Ovary Adenocarcinoma Primary tumor ER positive
PR positive
[41,42]
OAW 42 Ovary Cystadenocarcinoma Metastatic site (ascites) [43,44]
PA1 Ovary Teratocarcinoma Metastatic site (ascites) [45]
Table 2 List of antibodies used for Western blot
Gene Protein forms
detected by
WB*
Species Type/clone Dilution Company
MMP-1 latent and
active
rabbit polyclonal 1:750 Biozol
MMP-2 latent and
active
rabbit polyclonal 1: 1000 Abcam
MMP-9 latent and
active
mouse 9D4.2 1: 500 Chemicon
MMP-
11
latent and
active
mouse SL 3.01 1: 500 Abcam
MMP-
13
latent and
active
mouse 87512 1: 500 R&D
MMP-
15
latent and
active
rabbit polyclonal 1: 500 Abcam
MMP-
23
latent and
active
rabbit polyclonal 1: 1000 Abcam
MMP-
24
latent and
active
rabbit polyclonal 1: 1000 Abcam
MMP-
28
not specified rabbit polyclonal 1: 1000 Abcam
b-actin mouse M/Abcam
8226
1:
10.000
Abcam
*WB: Western blot.
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The intensity of ethidium-bromide luminescence and
protein expression in Western Blot images was quanti-
fied densitometrically using ImageJ image-processing
software package (ImageJ: National Institutes of Health,
Bethesda, MD, USA), as abovementioned, and normal-
ized in respect to the corresponding fragment concen-
tration of the ubiquitously expressed genes PBGD and
b-actin. Four different expression levels were considered
in respect of their densitometric value. Value 0 was con-
s i d e r e dt ob en oe x p r e s s i o n .V a l u e sb e t w e e n1a n d1 9
were considered as very weak ((+)), between 20 and 49
as weak (+), between 50 and 79 as moderate (++) and
between 80 and 100 as high (+++) expression.
Results
Expression of MMP mRNA in different gynecological
cancer cell lines
A varying expression pattern of MMPs could be observed
on an mRNA level, depending on the cell line investi-
gated. Except for MMP-16, -20, -25, -26 and -27, mRNA
could be detected for all other MMPs in at least one of
the cell lines. For MMP-8, -12 and -21 only very weak
mRNA expression could be observed in single cell lines.
Nine MMPs, which were present in most of the cell lines,
were chosen for further expression analysis on protein
level. The results of the semiquantitative RT-PCR and
W e s t e r nb l o ta r es u m m a r i z e di nF i g u r e s1a n d2 .T h e
results of the densitometrically quantified expression of
the mRNAs and proteins are shown in Table 3 and 4,
respectively. The enzymatic activity of two gelatinases
(MMP-2 and -9) in the serum-free cell culture superna-
tants was examined by gelatin zymography and the corre-
sponding data is presented in Figure 3.
Expression of MMPs in endometrial cancer cell lines
In the Ishikawa cell line, the highest expression was
detected for MMP-2 and -11 on an mRNA level, but only
a weak expression of their proteins could be observed in
the cell lysates. However, moderate gelatinolytic activity
of the secreted latent form of MMP-2 could be identified
by gelatin zymography, whereas its active form showed
very weak activity. For MMP-23, moderate mRNA and
strong expression of its inactive protein was seen in the
same cell line. Albeit the highest expression of MMP-24
mRNA was detected in Ishikawa cells, on Western blot
i t se x p r e s s i o nw a sw e a k e rc o m p a r e dt oo t h e rt w o
endothelial cancer cell lines. In Ishikawa, the expression
of MMP-28 both on mRNA as well as on protein level
was weaker compared to the two other endothelial can-
cer cell lines. In addition, MMP-7, -14, -17 and -19 were
detected in the Ishikawa cells by RT-PCR only.
Although the highest expression of MMP-11 mRNA was
identified in the HEC-1-A cells, no protein expression was
detectable in this cell line. The same cell line showed a
weak expression of MMP-2 on mRNA level, a moderate
expression on protein level as well as corresponding gelati-
nolytic activity of its secreted protein. Even though the
expression of MMP-23 mRNA was the weakest among
endometrial cancer cell lines, for its inactive form as well
as active protein strong expression was observed. A high
expression of proteins of approximately 65 KDa and 55
KDa could be identified for MMP-24 in HEC-1-A cells,
whereas for MMP-28 a strong expression of three protein
bands of approximately 62 KDa, 58 KDa and 48 KDa
could be seen. Additionally, very weak expression of
MMP-1 and -7 could be also detected in this cell line, but
only on mRNA level.
The highest expression of active forms of MMP-2 and
-11 proteins among the three examined endometrial cell
lines was detected in AN3 CA cells, although for MMP-
2 only a weak mRNA expression could be identified. In
this cell line, MMP-23 showed similar mRNA and pro-
tein expression patterns like in HEC-1-A. For MMP-24
and -28 the expression was detected on both, mRNA
and protein level, whereas for MMP-1 and -17 only
mRNA could be identified.
Expression of MMPs in cervical cancer cell lines
The majority of the analyzed MMPs could be identified
in all three cervical cell lines examined by RT-PCR.
While for MMP-2 a moderate to strong expression of
its mRNA could be found in HeLa, Caski and SiHa
cells, on protein level a very strong expression of its
inactive form was detected by Western blot. In addition,
using gelatin zymography we showed that all three of
these cultivated cell lines were secreting corresponding
amount of the latent form of MMP-2 in serum-free
medium. Furthermore, MMP-1, -3, -7, -8, -9, -11, -13,
-14, -15, -17, -23 and -24 all showed diverse expression
levels of their mRNAs with the highest expression level
in the Caski cell line. Active protein forms of MMP-1
and -11, inactive protein form of MMP-15, and both
inactive and active MMP-9, -13 and -23 were observed
on Western blot. For MMP-24, we were able to detect a
band of approximately 65 KDa in Caski and an addi-
tional band of approximately 55 KDa in HeLa cells.
Lastly, all three cervical cancer cell lines four protein
bands of approximately 62, 50, 48 and 46 kDa were
found for MMP-28.
Expression of MMPs in chorioncarcinoma cell lines
Albeit a clear expression existed of MMP-2, -9, -11, -14
and -19 mRNAs in the JEG cell line, their proteins
could not be detected using Western blot analysis. The
only proteins found in this cell line were the latent
forms of MMP-15 and -23 at moderate levels corre-
sponding to the expression of their mRNAs.
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Page 4 of 12Figure 1 MMP pattern in human gynecological cancer cell lines analyzed by semiquantitative RT-PCR. Total mRNA from the folowing
gynecological cancer cell lines was extracted and used as template for RT-PCR analysis: endometrium carcinoma (Endo-CA), cervical carcinoma
(Cervix-CA), chorion carcinoma (Chorio-CA), ovarian carcinoma (OV-CA) and teratocarcinoma (Terato-CA). Primers, specific for each transcript were
designed in flanking exons (for primer deteils see [46]), resulting in longer amplicons if human genomic DNA was amplified (positive control (+))
and in shorter amplicons representing cDNAs. The housekeeping gene PBGD was used as internal loading control and amounts of cDNA were
normalized to the amount of PBGD for each sample.
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Page 5 of 12A strong expression of MMP-2 mRNA was detected
in JAR cells. Extremely robust gelatinolytic activity of its
secreted protein could be identified in the serum-free
medium, whereas on Western blot only a moderate pro-
tein expression of the inactive form could be seen in the
cells. Active MMP-9 showed very weak gelatinolytic
activity, although on Western blot no expression could
be seen. Weak expression of both mRNAs and inactive
protein forms of MMP-11 and -23 could also be identi-
fied in this cell line. In addition, expression of MMP-14
and -19 was detected but only on mRNA level.
The highest expression found in all cell lines tested of
the active protein forms of MMP-2 and -11 was detected
in BeWo cells. Gelatin zymography also revealed activity
of MMP-2 secreted by BeWo cells. For MMP-15, a
strong expression of its mRNA was present but the latent
protein form could only be detected in those cells.
Further, solely MMP-14, -17, -19 and -24 could be identi-
fied by RT-PCR only.
Expression of MMPs in ovarian and teratocarcinoma cell
lines
A strong expression of the mRNA and protein (approxi-
mately 65 KDa and 55 KDa) of MMP-24 was found in
the ovarian carcinoma derived BG1 cells. Rather, a weak
expression of MMP-2 and -11 was also seen on Western
blot in this cell line.
For MMP-2, -15 and -24, a moderate expression of
mRNAs and latent protein forms were detected in the
OAW-42 cell line. Regarding OAW-42 cells, MMP-11
Figure 2 Protein expression of MMPs in different human gynecological cancer cell lines as analyzed by Western blot. Protein lysates
were isolated from the gynecological cancer cell lines and separated by polyacrylamid gel electrophoresis. Expressed MMP proteins were
visualized using specific antibodies, capable of recognizing both, the inactive and active, smaller forms of MMPs (antibodies are summarized in
Table 2). b-actin was used as internal loading control.
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Page 6 of 12Table 3 Expression levels of MMP mRNA in gynecological cancer cell lines
Ishikawa HEC-1-A AN3 CA Hela Caski SiHa JEG JAR BeWo BG-1 OAW-42 PA1
MMP1 0 (+) + (+) +++ +++ 0 0 0 0 (+) +++
MMP2 +++ + (+) + +++ +++ +++ +++ +++ (+) + +
MMP3 0 0 0 (+) +++ ++ 0 0 0 0 0 +++
MMP7 (+) + (+) (+) +++ 0 0 0 0 0 ++ (+)
MMP8 0 0 0 0 (+) 0 0 0 0 0 0 0
MMP9 0 0 0 (+) (+) + +++ 0 0 0 (+) +
MMP10 000 0 + + 0 0 0 0 0 + +
MMP11 ++ ++ ++ + ++ ++ +++ + +++ (+) ++ ++
MMP12 0 0 0 0 (+) 0 0 0 0 0 0 0
MMP13 0 0 0 + +++ + 0 0 0 0 0 +
MMP14 + 0 0 (+) +++ +++ +++ ++ +++ 0 + +++
MMP15 0 0 0 + +++ +++ + 0 +++ 0 + +
MMP16 0 0 0 000 0 000 0 0
MMP17 ++ 0 + + ++ ++ 0 0 + 0 (+) (+)
MMP19 (+) 0 0 0 0 0 +++ +++ +++ 0 + ++
MMP20 0 0 0 000 0 000 0 0
MMP21 0 0 0 000 0 000 0 ( + )
MMP23 ++ 0 0 (+) (+) ++ + (+) (+) 0 (+) (+)
MMP24 ++ + (+) ++ (+) ++ 0 0 + ++ ++ +
MMP25 0 0 0 000 0 000 0 0
MMP26 0 0 0 000 0 000 0 0
MMP27 0 0 0 000 0 000 0 0
MMP28 (+) + ++ (+) +++ ++ 0 0 0 0 0 ++
Scored from 0 = no expression, (+) = very weak expression, + = weak expression, ++ = moderate expression to +++ = high expression.
Table 4 Expression of MMP proteins in different gynecological cancer cell lines
Ishikawa HEC-1-A AN3 CA Hela Caski SiHa JEG JAR BeWo BG-1 OAW-42 PA1
proMMP1 0 0 0 000 0 000 0 0
MMP1 0 0 0 +++ 0 00 0 0 0
proMMP2 (+) + (+) +++ +++ +++ 0 + 0 0 ++ 0
MMP2 + + ++ 0 0 0 0 0 +++ 0 0 0
proMMP9 0 0 0 +++ 0 00 0 + 0
MMP9 000 + + + 0 0 0 0 0 + + 0
proMMP11 0 (+) (+) 0 0 0 0 + 0 0 +++ 0
MMP11 + 0 +++ ++ + ++ 0 + + (+) (+) +
proMMP13 0 0 0 (+) (+) (+) 0 0 0 0 0 0
MMP13 0 0 0 +++ (+) ++ 0 0 0 0 0 0
proMMP15 0 0 0 ++ ++ +++ + 0 ++ (+) + ++
MMP15 0 0 0 (+) 0 0 0 0 0 0 0 0
proMMP23 +++ +++ ++ ++ + + + (+) 0 0 (+) +
MMP23 (+) ++ ++ +++ + ++ 0 0 0 0 ++ +
proMMP24 + ++ ++ + + ++ 0 0 0 ++ + +++
MMP24 (+) ++ ++ + (+) 0 0 0 0 + + +
MMP28(62) + +++ ++ ++ ++ +++ 0 0 0 0 0 0
MMP28(58) +++ +++ +++ 0 0 0 0 0 0 0 0 0
MMP28(50) +00 + 0 + 0 0 0 0 0 0
MMP28(48) ++ +++ +++ + 0 + 0 0 0 0 0 0
MMP28(46) + ++ ++ (+) 0 (+) 0 0 0 0 0 0
Scored from 0 = no expression, (+) = very weak expression, + = weak expression, ++ = moderate expression to +++ = high expression.
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Page 7 of 12showed strong expression of its inactive protein whereas
for MMP-9 and -24 moderate expressions of both inac-
tive and active proteins were identified. Zymographic
analysis of the serum-free cell culture supernatant iden-
tified strong gelatinolytic activity of latent MMP-2 as
well as weak activity of active MMP-9. Additionally,
expression of MMP-7, -14 and -19 was detected on a
mRNA level.
The highest expression was detected for MMP-1 on
mRNA level in the teratocarcinoma cell line PA-1 but
no corresponding protein expression could be detected
by Western blot analysis. Secreted MMP-2 showed weak
gelatinolytic activity. For MMP-11 moderate mRNA and
protein expression was seen in this cell line and moder-
ate expression of MMP-15 mRNA and inactive protein
form could be observed herein, whereas for MMP-23 a
weak expression could be observed by RT-PCR and
Western blot. Although only a weak expression of
MMP-24 mRNA was detected in PA-1 cells, a strong
expression of two protein bands of 65 KDa and approxi-
mately 55 KDa were seen in Western blot. The PA-1
cell line was the only one amongst the investigated cell
panel which showed a weak PCR product for MMP-21.
Discussion
Degradation of the extracellular matrix is a condition for
invasive growth of malignant tumors. Metalloproteinases
(MMPs) play a very important role in this process. The
role and the contribution of the tumor and stromal cell
compartments to the increased levels of MMPs in carci-
noma tissue are still poorly understood. Some investiga-
tors suggest an almost exclusive stromal origin of
MMPs detected in cancer tissue [1]. Other studies
demonstrate that a lot of MMPs are constitutively
expressed in several tumor cell lines in the absence
from any stromal component [18]. Our objective was to
investigate which MMPs are expressed in different gyne-
cological cancer cell lines and thus to identify useful
model system for further analysis on MMP regulation in
cancer.
MMP-2, -7 and -9 were found to be expressed in uter-
ine serous carcinoma as well as in endometrioid carci-
noma of the uterus by immunohistochemistry [49]. The
endometrial carcinoma derived cell line Ishikawa was
shown to secrete MMP-1, -2 and -9 [50]. However in our
Ishikawa cell line, mRNA and protein could be detected
for MMP-2 but not for MMP-1 and -9, which could be
influenced by different primers used or different cell cul-
ture conditions that might affect MMP expression.
MMP-1 was described in HEC-1-A and AN3 CA cells
[24] and in those cell lines we found a corresponding
expression of its mRNA. However, no expression could
be identified for MMP-1 protein in those endometrial
cell lines. Our results confirm those of Park et al., who
did not detect MMP-9 mRNA in HEC-1-A cells using
RT-PCR [51]. Whereas in contrast to our negative find-
ings by Western Blot, MMP-1, -2, -7, -9 and -14 protein
could be detected in HEC-1-A cells using immunohisto-
chemistry by Tanaka [52]. These differences might be
due to different culture conditions or primers and anti-
bodies (and techniques - WB versus immunohistochem-
sitry) used. Also, mRNA stability of MMP transcripts
contributes to the metalloproteinase product amount.
There is evidence about the regulation of the MMP-9
mRNA stability by a3b1 integrin, among others, that is
associated with mammary carcinoma cell metastasis and
invasion [53,54]. Modulation of its mRNA stability might
be important during malignant conversion and metasta-
sis, when tumor cells need to induce or maintain MMP-9
levels in response to changing environmental cues. In
endometrial cancer, a high expression of MMP-2 and low
expression of TIMP-2 seem to be potent markers for
tumors, which provide a high risk of local and distant
metastasis [55]. In our study MMP-2 mRNA as well as
MMP-2 protein was found in all three endometrial can-
cer cell lines. We also identified moderate gelatinolytic
Figure 3 Analysis of the cell culture supernatants by gelatin zymography. The cell lines were first plated in serum-containing medium for
72 h. Afterwards, medium was replaced by serum-free DMEM/HamsF12 for an additional 48 h. Samples of conditioned medium were assayed
for MMP-2 and MMP-9 by gelatin zymography. Gelatinolytic activity of pro and active MMP-2 and active MMP-9 are visible as a clear area on the
gel, indicating where the gelatine has been digested.
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and HEC-1-A cells. Expession analysis of TIMPs, includ-
ing TIMP-2, remains to be done however in our endo-
metrial cancer cell lines. A relation between higher
expression of MMP-2 and -9 and progression of endome-
trial carcinoma was detected by Di Nezza et al. using in
situ hybridization and in situ zymography. MMP-2, -9
and -14 were mainly localized in epithelial tumor cells,
whereas only a variable stromal localization could be
detected [56]. They also found a co-localization of MMP-
14 with MMP-2, supporting the role of MMP-14 in the
activation of pro-MMP-2. In our cell lines, only Ishikawa
was found positive for MMP-14 mRNA. However, pro-
tein detection in the Western blot was not possible by
the antibodies available. Maximum levels of MMP-26
mRNA were found in normal endometrial tissue and in
endometrial hyperplasia, whereas the amount of MMP-
26 mRNA was downregulated in all malignant samples
investigated [57]. Consequently, in our study none of the
tested endometrial cancer cell lines was positive for
MMP-26 mRNA. This finding further fits to the data by
Isaka and co-workers, where all but one endometrial
tissue sample as well as all endometrial cancer cell lines
including HEC-1-A were negative for MMP-26 mRNA
[58]. In contrast to our results, as we found a weak
expression of MMP-7 mRNA in HEC-1-A cells, they did
not detect MMP-7 mRNA in this cell line. This differ-
ence might be due to either different primers or condi-
tions used, or to different cell culture conditions that
may influence MMP expression [59]. To the best of our
knowledge, there are no available data in literature about
the expression of the other MMPs in endometrial cancer
cell lines. According to our results, the Ishikawa cell line
showed the broadest range of mRNA and protein expres-
sion of most of the MMPs analyzed and thus could be
the best choice as model cell line for future experiments
on the role of MMPs in endometrial carcinoma develop-
ment and as a positive control for MMP research. The
expression of MMP-11, -23, -24 and -28, which was iden-
tified in our study on both, mRNA and protein level,
could be related to the development of endometrial carci-
noma and awaits further investigation in this cancer
entity. Remarkably, the expression of MMP-23 protein
was however on higher level compared to its mRNA,
which might be due to increased efficiency of MMP-23
translation in endometrial cancer. Using the antibody for
MMP-28 we detected bands of approximately 62, 58, 50,
48 and 46 kDa. However, we did not have enough data to
discriminate inactive and active forms of this protein
since there is barely any information about its protein
size. At least three MMP-28 transcripts of 2.6, 2.0, and
1.2 kb have been reported representing alternatively
spliced forms, differentially expressed in human tissues
[60] and isoforms which encode proteins of 520 and 393
amino acids with predicted respective masses of 58.9 and
44.5 kDa.
In the cervix, it was shown that MMP-2, -3 and -9 are
present in the tissue of cervical adenocarcinomas,
whereas no expression of these MMPs could be detected
in the nonneoplastic endocervical epithelium [10]. In
accordance to this, Wang et al. detected a higher
expression of MMP-2 mRNA in cervical carcinomas
then in normal counterparts of the uterine cervix [12]
and we found MMP-2 mRNA in all three cervical carci-
noma derived cell lines as well. We also found a strong
expression of inactive MMP-2 in those cells using Wes-
tern blot as well as a strong gelatinolytic activity of its
secreted protein. The high expression of MMP-14
described by Zhai and colleagues in tissues of cervical
carcinomas corresponds to our finding of strong mRNA
expression in Caski and SiHa cell lines [13]. Further, we
found a strong expression of MMP-15 mRNA in those
cell lines. These results are in line with results obtained
by Iwasaki et al. [19]. In contrast to our study Iwasaki
and co-workers did not detect MMP-1 in Caski or SiHa
cells, whereas we found a strong expression of MMP-1
mRNA and a weak expression of active MMP-1 in both
cell lines. In HeLa cells, only few MMPs were expressed
at lower amounts. Taken together the identified expres-
sion profile leads to the conclusion that future experi-
ments on invasion of cervical cancer cells would be
promising using Caski or SiHa cells as a model. In addi-
t i o n ,s i n c eM M P - 1 ,- 1 1 ,- 1 3 ,- 1 5 ,- 1 7 ,- 2 4a n d- 2 8a r e
expressed in all three cervical carcinoma cell lines ana-
lyzed, these could be good candidates for further expres-
sion analysis in cervical carcinoma tissues as well.
To our knowledge, there are just few amount of data
available about the expression of MMPs in chorioncarci-
noma cell lines. In the JEG cell line we detected MMP-2,
-9, -11, -14, -15, -19 and -23 mRNA whereas on protein
level only weak expression of latent MMP-15 and -23
was observed. Giambernardi et al. also investigated the
expression of the abovementioned MMPs in JEG cells
and observed the expression of MMP-12 (which was
negative in our results) and -14, but not the expression of
the remaining MMPs [18]. These differences may be due
to some variations in cell culture conditions (e.g. differ-
ences in serum containing growth factors added to the
culture medium). We found a moderate to strong expres-
sion of MMP-2, -11, -14, -15 and -19 mRNA in BeWo
cells, whereas on protein level only proMMP-15 and
active MMP-2 and -11 were detectable. In addition, our
zymography analysis of secreted MMP-2 identified mod-
erate gelatinolytic activity of its latent and active forms.
These differences in the expression pattern between
mRNA and protein level might be due to regulation of
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Page 9 of 12the translational level [61]. In line with our results, the
expression of MMP-2 was already described in BeWo
cells [62]. Our data about the expression pattern of
MMPs in the JAR cell line showed a week to moderate
expression of MMP-2, -11, -14, -19 and -23 on mRNA
level, but only a weak expression of MMP-11 and -23
protein could be identified. However, for MMP-2 we
were able to detect protein expression in the cells as well
as very strong gelatinolytic activity of its secreted protein.
Thus, based on our analysis, we suggest BeWo cells as
the best model for future analyses of MMP biology and
regulation in chorioncarcinoma cell lines.
In ovarian cancer, MMP-2 and -9 seem to be expressed
more frequently in early lesions than in established carci-
nomas [14]. Overexpression of MMP-2, -9 and -14 seems
to also prepare the ground for development and growth
of malignant ovarian tumors [16]. According to these
f i n d i n g s ,M M P sm i g h tp l a yac r i t i c a lr o l ei nt h ef i r s t
steps of tumorigenesis in ovaries. Surprisingly, to our
knowledge, no single study to date investigated the
expression of MMPs in the ovarian cancer cell lines
OAW-42, BG-1 and in the teratocarcinoma cell line
PA-1 compared to already performed examinations of
endometrial, cervix or choriocarcinoma cancer cell lines,
as already discussed. The PA-1 cells do express a rela-
tively broad range of 15 different MMP-RNAs. While on
mRNA level only a weak expression of MMP-15 and -24
could be observed a moderate to strong expression of
pro-MMP-15 and -24 proteins was detectable. Further,
the active form of MMP-11 and both, inactive and active
forms of MMP-23 were detected. OAW-42 cells showed
ar e m a r k a b l eh i g he x p r e s s i o no fM M P - 1 1a sm R N Aa n d
protein. Further, mRNAs and proteins of MMP-2, -9, -15
and -23 were moderately expressed in this cell line.
According to this finding we also detected gelatinolytic
activity of secreted MMP-2 and MMP-9 by performing
zymography analysis of the cell culture supernatant.
B a s e do no u rd a t a ,t h e r ea r em a n ym o r eM M P sb e s i d e
the commonly investigated MMP-2, -9 and -14, which
are expressed in ovarian cancer cell lines and are thus
candidates for future analyses on their influence on the
development of ovarian cancer.
In our study we could not detect the mRNAs of
MMP-12, -16, -20, -25, -26 and -27 in any of the twelve
cell lines analyzed. However due to the genomic DNA
control and the positive other MMPs in the same pre-
parations, we could ascertain that the RT-PCR itself
worked. Concerning MMP-20, these results are in line
with results obtained by Giambernardi et al. who also
did not detect MMP-20 in any of the eighty-four cell
lines analyzed in their study [18].
In summary, we detected a broad and diverse expres-
sion pattern of MMPs in different cell lines representing
different human gynecological cancer entities. Our data
indicate that there is no real pattern of MMP expression
related to cancer type or metastasis. Even within the
same cancer stage MMPs have a diverse expression, as
our previous analysis of breast cancer and glioblastoma
showed [46,63]. Therefore, further studies on MMPs
and a better understanding of their role in tumor inva-
sion and metastasis are necessary. The results presented
here could establish thus a basis for the analysis of the
regulation of MMP expression in gynecological tumors,
which could be performed in these cell lines selected as
a model system.
Conclusions
This study demonstrates that gynecological cell lines
grown in vitro and therefore being independent of envir-
onmental factors can constitutively express a wide variety
of MMPs on mRNA and protein level. MMP-2, -11, -14
and -24 are found in most of the cell lines analyzed.
MMP-1 and -7 were expressed in all but chorioncarci-
noma cells, whereas MMP-9 and -15 showed the same
expression pattern concerning endometrial cancer cell
lines. In addition, MMP-3, -10 and -13 were expressed in
cervical carcinoma and teratocarcinoma cell lines only.
Caski and PA-1 cell lines could be the best choice for
all future experiments on the regulation of MMPs and
their role in gynecological cancers. Additionally, the PA-
1 cell line showed the strongest mRNA and protein
expression of most of the MMPs analyzed and therefore
could be used as the positive control for their expression
analysis in general. These cell lines are also promising
candidates for future investigations dealing with the role
of MMPs in tumor invasion and building of metastatic
formations. Although expression on mRNA and protein
level was quite less in comparison to the abovementioned
cell lines, BeWo cells could be the best choice for future
experiments concerning chorioncarcinoma cell lines and
the Ishikawa cell line concerning endometrial carcinoma,
whereas OAW could be used for the ovarial cancer
analysis.
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